Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: Follow-up data from European Vasculitis Study Group clinical trials

Annals of the Rheumatic Diseases

Volumn 70, Issue 8, 2011, Pages 1415-1421

  Heijl, C ^a   Harper, L ^b   Flossmann, O ^c   Stucker I ^d   Scott, D G I ^e   Watts, R A ^f   Hoglund P ^a   Westman, K ^a   Mahr, A ^g  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^d INSERM   (France)

^e NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^g Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANCA ASSOCIATED VASCULITIS; ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STANDARDIZED INCIDENCE RATIO;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; AZATHIOPRINE; CYCLOPHOSPHAMIDE; EPIDEMIOLOGIC METHODS; EUROPE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS;

EID: 79959805570     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.145250     Document Type: Article

References (39)

1. Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011;70:704.
2. Savage CO, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997;349:553-8. (Pubitemid 27092803)
3. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23. (Pubitemid 27495778)
4. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94.
5. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481-90. (Pubitemid 40663940)
6. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008;59:794-9. (Pubitemid 351847561)
7. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62. (Pubitemid 32173312)
8. Hannuksela-Svahn A, Pukkala E, Läärä E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-90. (Pubitemid 30415349)
9. Grulich AE, van Leeuwen MT, Falster MO, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67. (Pubitemid 47017468)
10. Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5.
11. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
12. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82-5. (Pubitemid 34602069)
13. Westman KW, Bygren PG, Olsson H, et al. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52. (Pubitemid 28209094)
14. Grosse Y, Baan R, Straif K, et al. A review of human carcinogens-Part A: pharmaceuticals. Lancet Oncol 2009;10:13-14.
15. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9. (Pubitemid 41117433)
16. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
17. de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
18. Jayne DR, Gaskin G, Rasmussen N, et al. R andomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8. (Pubitemid 47041083)
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
20. Luqmani RA, Exley AR, Kitas GD, et al. Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997;11:423-46. (Pubitemid 27296604)
21. Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008;44:1345-89.
22. Office for National Statistics. Cancer Statistics: Registrations Series MB1 (MB1 No. 31 - Cancer Registration Statistics 2000. http://www.statistics. gov.uk/statbase/Product.asp?vlnk=8843 (accessed May 2010).
23. Engholm G, Ferlay J, Christensen N, et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Prediction in the Nordic Countries, version 3.6: Association of the Nordic Cancer Registries. Danish Cancer Society. http://www.ancr.nu (accessed May 2010).
24. Robert-Koch Institut. Daten zur Krebsinzidenz und -mortalität in Deutschland. http://www.rki.de/cln-178/nn-204130/DE/Content/GBE/DachdokKrebs/ Datenbankabfragen/datenbankabfragen-node.html?-nnn=true (accessed May 2010).
25. Remontet L, Buemi A, Velten M, et al. Évolution de l'incidence et de la mortalité par cancer en France de 1978 à 2000. http://www.invs.sante.fr/publications/2003/rapport-cancer-2003 (accessed May 2010).
26. AIRTUM: Associazione Italiana Registri Tumori. http://www.registri- tumori.it/cms/?q=database-airtum (accessed May 2010).
27. Institut für Krebsepidemiologie e.V. Registerstelle des Krebsregisters Schleswig-Holstein. http://www.krebsregister-sh.de/datenbank/ index.php (accessed May 2010).
28. Epidemiologisches Krebsregister Saarland. http://www.krebsregister. saarland.de/datenbank/datenbank.html (accessed May 2010).
29. Rothman KJ, Greenland S. Modern epidemiology. 2nd edn. Philadelphia, PA: Lippincott-Raven, 1998.
30. Sun J, Ono Y, Takeuchi Y. A simple method for calculating the exact confidence interval of the SMR with a SAS function. J Occup Health 1996;38:196-7. (Pubitemid 126491942)
31. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990;131:373-5. (Pubitemid 20118904)
32. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34. (Pubitemid 43049607)
33. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871-4. (Pubitemid 41325100)
34. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204. (Pubitemid 40450709)
35. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84. (Pubitemid 26070112)
36. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-38.
37. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44. (Pubitemid 41640845)
38. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med 2008;264:514-27.
39. Lucke TW, Hole DJ, Mackie RM. An audit of the completeness of non-melanoma skin cancer registration in Greater Glasgow. Br J Dermatol 1997;137:761-3. (Pubitemid 27496194)